Recombinant interleukin-2 pre-treatment increases anti-tumor response to paclitaxel by affecting lung P-glycoprotein expression on the Lewis lung carcinoma

Anti-Cancer Drugs

Volumn 17, Issue 2, 2006, Pages 195-199

  Hosten, Benoît ^a   Challuau, Désiré ^b   Gil, Sophie ^a   Bouquet, Céline ^c   Marion, Sylvie ^d   Perricaudet, Michel ^c   Di Palma, Mario ^b   Farinotti, Robert ^a   Bonhomme Faivre, Laurence ^a,d  

^a Pharmaceutical Sciences   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CNRS   (France)

^d HÔPITAL PAUL BROUSSE   (France)

Author keywords

Lewis lung carcinoma; Lung metastasis; P glycoprotein; Paclitaxel; Recombinant interleukin 2

Indexed keywords

GLYCOPROTEIN P; PACLITAXEL; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; FEMALE; LEWIS CARCINOMA; LUNG CARCINOMA; LUNG METASTASIS; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CARCINOMA, LEWIS LUNG; COMBINED MODALITY THERAPY; FEMALE; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; LUNG; MICE; MICE, INBRED C57BL; P-GLYCOPROTEIN; PACLITAXEL; RECOMBINANT PROTEINS;

EID: 33646262077     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200602000-00011     Document Type: Article

References (19)

1. Wiseman JR, Spencer CM. Paclitaxel: an update of its use in the treatment of metastatic breast cancer and ovarian and other gynecological cancers. Drugs Aging 1998; 12:305-334.
2. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, et al. Taxol: a unique antineoplasic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111:273-279.
3. Jamois C, Comets E, Mentré F, Marion S, Farinotti R, Bonhomme-Faivre L. Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2. Cancer Chemother Pharmacol 2005; 55:61-71.
4. Callies S, De Alwis DP, Harris A, Vasey P, Beijnen JH, Schellens JH, et al. A population pharmacokinetic model for paclitaxel in the presence of a novel P-gP modulator, Zosuquidar trihydrochloride (LY335979). Br J Clin Pharmacol 2003; 56:46-56.
5. Allen JD, Brinkhuis R F, van Deemter L, Wijnholds J, Schinkel AH. Extensive contribution of the multidrug transporters P-glycoprotein and MDR 1 to basal drug resistance. Cancer Res 2000; 60:5761-5766.
6. Parekh H, Wiesen K, Simpkins H. Acquisition of Taxol resistance via P-glycoprotein and non P-glycoprotein mechanisms in human ovarian carcinoma cells. Biochem Pharmacol 1997; 53:461-70.
7. Kruijtzer CMF, Schellens JHM, Mezger J, Scheulen ME, Keilholz U, Beijnen JH, et al. Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J Clin Oncol 2002; 20:4508-4516.
8. Kimura Y, Aoki J, Kohno M, Ooka H, Tsuruo T, Nakanishi O. P-glycoprotein inhibition by multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother Pharmacol 2002; 49:322-328.
9. Chiou JK, Liang JA, Hsu WH, Wang JJ, Ho ST, Kao A. Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung 2003; 181:267-273.
10. Stein U, Wather W, Shoemaker RH. Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance. Br J Cancer 1996; 74:1384-1391.
11. Bonhomme-Faivre L, Pelloquin A, Tardivel S, Urien S, Mathieu MC, Castagne V, et al. Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice. Anticancer drugs 2002; 13:51-57.
12. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 147:187-376.
13. Tourani JM. Immunothérapie et immunomodulation. Oncologie 2002; 43:1-7.
14. Qin Y, Hokland ME, Bryant JL, Yuquing Z, Nannmark U, Watkins RH, et al. Tumor localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases. Int J Cancer 2003; 105:512-519.
15. Chadi A, Rouchon C, Hosten B, Farinotti R, Bonhomme-Faivre L. Enhanced oral bioavailability of paclitaxel by recombinant interleukin-2 with murine Lewis lung carcinoma. Drug Metab Drug Interact 2004; 20:219-229.
16. Orlawski S, An D, Belehradek Jr J, Mir L. Antimetastatic effects of electrochemotherapy and of histoincompatible interleukin-2-secreting cells in the murine Lewis lung tumor. Anticancer Drugs 1998; 9:551-556.
17. Rose WC. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. J Natl Cancer Inst Monogr 1993; 15:47-53.
18. Kitasono M, Sumizawa T, Takebayashi Y, Chen ZS, Furukawa T, Nagayama S, et al. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 1999; 91:1647-1653.
19. Mustafa A, McKallip RJ, Fisher M, Duncan R, Nagarkatti PS, Nagarkatti M. Regulation of interleukin-2-induced vascular leak syndrome by targeting CD44 using hyaluronic acid and anti-CD44 antibodies. J Immunother 2002; 25:476-488.